<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01179984</url>
  </required_header>
  <id_info>
    <org_study_id>BPV-09-006</org_study_id>
    <nct_id>NCT01179984</nct_id>
  </id_info>
  <brief_title>Bard® LifeStent® Vascular Stent Delivery System Study</brief_title>
  <official_title>Bard® LifeStent® Vascular Stent Delivery System Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>C. R. Bard</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>C. R. Bard</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness and safety of a new delivery
      system for the Bard® LifeStent® Vascular Stent System.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single-arm, non-randomized, prospective, multi-center study using the Bard® LifeStent®
      Vascular Stent Delivery System in subjects with lifestyle-limiting claudication or ischemic
      rest pain that are candidates for percutaneous transluminal angioplasty (PTA) and stenting
      with lesion(s) in the infra-inguinal segment (superficial femoral artery (SFA) and/or
      proximal popliteal artery). Subjects will be treated with PTA followed by implantation of the
      Bard® LifeStent® Vascular Stent.

      Clinical follow-up for all subjects will be performed prior to hospital discharge, 30-days,
      and 12-, 24-, and 36-months post-index procedure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Effectiveness: Percentage of Stents With Successful Delivery</measure>
    <time_frame>At implantation (Day 0)</time_frame>
    <description>Effectiveness:
Acute effectiveness defined as the successful delivery of the stent with the post-deployment stent length being within 10% of the pre-deployment length.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>(Safety) Freedom From Occurrence of Death, Amputation and TVR/TLR at 30-days Post-index Procedure.</measure>
    <time_frame>30 day follow-up</time_frame>
    <description>Safety:
Freedom from occurrence of death, amputation and TVR/TLR at 30-days post-index procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary Target Lesion Patency</measure>
    <time_frame>12 months post-index procedure</time_frame>
    <description>Percentage of participants with Primary Target Lesion Patency (TLP) at 12 months post-index procedure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Peripheral Vascular Disease</condition>
  <arm_group>
    <arm_group_label>PTA and study stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bard® LifeStent® Vascular Stent System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bard® LifeStent® Vascular Stent System</intervention_name>
    <description>Stent Implantation</description>
    <arm_group_label>PTA and study stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject or legal representative has been informed of the nature of the evaluation,
             agrees to its provisions, and has signed the informed consent form (ICF).

          2. Subject agrees to comply with the protocol-mandated follow-up procedures and visits.

          3. The subject is ≥ 21 years old.

          4. Female subjects of childbearing potential must have a negative urine or serum
             pregnancy test within seven days prior to index procedure. Female subjects who are
             surgically sterile or post-menopausal are exempt from having a pregnancy test.

          5. The subject has lifestyle-limiting claudication or ischemic rest pain defined as:
             Rutherford Category1 2-4 (moderate claudication to ischemic rest pain).

          6. The target lesion(s) has angiographic evidence of stenosis or restenosis ≥50% or
             occlusion (by visual estimate) and is amenable to PTA and stenting.

          7. The total treated segment(s) must be ≤ 240 mm.

          8. The target vessel reference diameter is ≥4.0 mm and ≤6.5 mm (by visual estimate) and
             therefore appropriate for treatment with available stent diameters of 6.0 mm and 7.0
             mm.

          9. There is angiographic evidence of at least one vessel runoff to the foot (at the level
             of the malleolus).

        Exclusion Criteria:

          1. The subject is unable or unwilling to provide informed consent or is unable or
             unwilling to comply with the study follow-up procedure and visits.

          2. The subject has claudication or critical limb ischemia described as Rutherford
             Category1 1 (mild claudication), 5 (minor tissue loss) or 6 (major tissue loss).

          3. The subject has a known contraindication (including allergic reaction) or sensitivity
             to antiplatelet/anticoagulant medications, nickel, titanium or tantalum.

          4. The subject has a known sensitivity to contrast media that is not amenable to
             pretreatment with steroids or/and antihistamines.

          5. The subject has a history of bleeding diatheses or coagulopathy.

          6. The subject has concomitant renal failure with a creatinine of &gt;2.5 mg/dL.

          7. The subject has concomitant hepatic insufficiency, thrombophlebitis, uremia, systemic
             lupus erythematosus (SLE), or deep vein thrombosis (DVT) at the time of the study
             procedure.

          8. The subject is receiving dialysis or immunosuppressive therapy.

          9. The subject is participating in an investigational drug or another investigational
             device study.

         10. The subject has another medical condition, which, in the opinion of the investigator,
             may cause him/her to be non-compliant with the protocol, confound the data
             interpretation, or is associated with limited life expectancy of less than two years.

         11. The subject has extensive peripheral vascular disease, which, in the opinion of the
             investigator, precludes safe insertion of an introducer sheath.

         12. The target lesion(s) is located within an aneurysm or associated with an aneurysm in
             the vessel segment either proximal or distal to the target lesion(s).

         13. The subject has angiographic evidence of poor inflow, which would be deemed inadequate
             to support a vascular bypass graft.

         14. The subject is diagnosed with septicemia at the time of the study procedure.

         15. Patients with a stent previously implanted into the target vessel.

         16. Bilateral disease in the native SFA and/or proximal popliteal artery where both limbs
             meet the inclusion/exclusion criteria and it is planned to treat both limbs within 30
             days. Note: One limb may be enrolled in the study, but only if the second limb is
             planned to be treated after the 30-day follow-up visit has taken place. The limb that
             may be enrolled has to be the limb with the more severe lesion and the reasons for
             treating this specific limb will need to be stated in the CRF.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Zeller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herzzentrum Bad Krozingen, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univ. Prof. Dr. Johannes Lammer</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <state>Baden Württemberg</state>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Henrik Schroeder</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Hans Krankenberg</name>
      <address>
        <city>Hamburg</city>
        <zip>22527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Rainer Schmiedel</name>
      <address>
        <city>Kaiserslautern</city>
        <zip>67657</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Dr. med. Dietrich Pfeiffer</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Dr. Holger Reinecke</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Dr. Gunnar Tepe</name>
      <address>
        <city>Rosenheim</city>
        <zip>83022</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2010</study_first_submitted>
  <study_first_submitted_qc>August 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2010</study_first_posted>
  <results_first_submitted>November 9, 2016</results_first_submitted>
  <results_first_submitted_qc>January 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 9, 2017</results_first_posted>
  <last_update_submitted>January 18, 2017</last_update_submitted>
  <last_update_submitted_qc>January 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PTA and Study Stent</title>
          <description>The study population is comprised of subjects who present with lifestyle-limiting claudication or ischemic rest pain that are candidates for PTA and stenting.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline analysis population is comprised of subjects who present with lifestyle-limiting claudication or ischemic rest pain that are candidates for PTA and stenting.</population>
      <group_list>
        <group group_id="B1">
          <title>Single-Arm</title>
          <description>The study population is comprised of subjects who present with lifestyle-limiting claudication or ischemic rest pain that are candidates for PTA and stenting.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="76"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.1" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Acute Effectiveness: Percentage of Stents With Successful Delivery</title>
        <description>Effectiveness:
Acute effectiveness defined as the successful delivery of the stent with the post-deployment stent length being within 10% of the pre-deployment length.</description>
        <time_frame>At implantation (Day 0)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PTA and Study Stent</title>
            <description>The study population is comprised of subjects who present with lifestyle-limiting claudication or ischemic rest pain that are candidates for PTA and stenting.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Effectiveness: Percentage of Stents With Successful Delivery</title>
          <description>Effectiveness:
Acute effectiveness defined as the successful delivery of the stent with the post-deployment stent length being within 10% of the pre-deployment length.</description>
          <units>percentage of stents</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Stents</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Stents</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="90" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>(Safety) Freedom From Occurrence of Death, Amputation and TVR/TLR at 30-days Post-index Procedure.</title>
        <description>Safety:
Freedom from occurrence of death, amputation and TVR/TLR at 30-days post-index procedure.</description>
        <time_frame>30 day follow-up</time_frame>
        <population>Freedom from occurrence of death, amputation and TVR/TLR at 30-days post-index procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Single-Arm</title>
            <description>The study population is comprised of subjects who present with lifestyle-limiting claudication or ischemic rest pain that are candidates for PTA and stenting.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety) Freedom From Occurrence of Death, Amputation and TVR/TLR at 30-days Post-index Procedure.</title>
          <description>Safety:
Freedom from occurrence of death, amputation and TVR/TLR at 30-days post-index procedure.</description>
          <population>Freedom from occurrence of death, amputation and TVR/TLR at 30-days post-index procedure.</population>
          <units>percentage of freedom from events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Primary Target Lesion Patency</title>
        <description>Percentage of participants with Primary Target Lesion Patency (TLP) at 12 months post-index procedure</description>
        <time_frame>12 months post-index procedure</time_frame>
        <population>Primary Target Lesion Patency (TLP) at 12 months post-index procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>PTA and Study Stent</title>
            <description>The study population is comprised of subjects who present with lifestyle-limiting claudication or ischemic rest pain that are candidates for PTA and stenting.</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Target Lesion Patency</title>
          <description>Percentage of participants with Primary Target Lesion Patency (TLP) at 12 months post-index procedure</description>
          <population>Primary Target Lesion Patency (TLP) at 12 months post-index procedure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout follow-up of study period = 36 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PTA and Study Stent</title>
          <description>The study population is comprised of subjects who present with lifestyle-limiting claudication or ischemic rest pain that are candidates for PTA and stenting.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <description>This includes all AEs in the system organ class (SOC) that were reported by less than two subjects.</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Arterial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <description>This includes all AEs in the system organ class (SOC) that were reported by less than two subjects.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <description>This includes all AEs in the system organ class (SOC) that were reported by less than two subjects.</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Arterial Restenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>In-stent Arterial Restenosis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <description>This includes all AEs in the system organ class (SOC) that were reported by less than two subjects.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <description>This includes all AEs in the system organ class (SOC) that were reported by less than two subjects.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <description>This includes all AEs in the system organ class (SOC) that were reported by less than two subjects.</description>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Arterial restenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Arterial restenosis limb</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Femoral arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Femoral Arterial Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Iliac Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>In-stent arterial restenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <description>This includes all AEs in the system organ class (SOC) that were reported by less than two subjects.</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <description>This includes all AEs in the system organ class (SOC) that were reported by less than two subjects.</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <description>This includes all AEs in the system organ class (SOC) that were reported by less than two subjects.</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <description>This includes all AEs in the system organ class (SOC) that were reported by less than two subjects.</description>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Arterial restenosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>In-stent arterial restenosis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Post -procedural hematoma</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <description>This includes all AEs in the system organ class (SOC) that were reported by less than two subjects.</description>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <description>This includes all AEs in the system organ class (SOC) that were reported by less than two subjects.</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <description>This includes all AEs in the system organ class (SOC) that were reported by less than two subjects.</description>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Arterial restenosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Arterial stenosis lim</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Femoral arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Iliac artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate Director of Clinical Affairs</name_or_title>
      <organization>Bard Peripheral Vascular</organization>
      <phone>480-379-2838</phone>
      <email>josh.smale@crbard.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

